Clinical Trials on Tumor, Solid in United States

Total 9915 results

Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Genzyme, a Sanofi Company

Completed

SR-45023A in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Chicago
National Cancer Institute (NCI)

Terminated

Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Smokefree.Gov Website in Helping United States Federal Employees Quit Smoking

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C

Unspecified Adult Solid Tumor, Protocol Specific

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

KRN5500 in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

A New Radiation Therapy Planning System in Patients Undergoing Radiation Therapy for Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Computed Tomography in Detecting Movement of the Esophagus in Patients Undergoing Radiation Therapy to the Chest

Unspecified Adult Solid Tumor, Protocol Specific

United States
Gilead Sciences

Recruiting

Study of GS-4528 in Adults With Solid Tumors

Solid Tumor

Korea, Republic of, Taiwan, Canada, United Kingdom, Spain, United States
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

Solid Tumor

United States, China
Novartis Pharmaceuticals

Active, not recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) (LuMIERE)

Solid Tumor

United States
Intezyne Technologies, Inc.

Terminated

Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer

Neoplasms | Cancer | Tumors | Refractory Solid Tumors | Recurrent Solid Tumors

United States
Aprea Therapeutics

Recruiting

Study Of ATRN-119 In Patients With Advanced Solid Tumors (ABOYA-119)

Advanced Solid Tumor

United States
Tracon Pharmaceuticals Inc.

No longer available

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Solid Tumors

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A

Solid Tumors

United States
Daiichi Sankyo, Inc.
Medpace, Inc.

Completed

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Solid Tumors

United States
Herbert Hurwitz, MD
Novartis; Genentech, Inc.; Amgen

Completed

BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) (BEP)

Solid Tumors

United States
Herbert Hurwitz
Genentech, Inc.; Abbott

Completed

A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors

Solid Tumors

United States
Tracon Pharmaceuticals Inc.

Completed

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Adult Solid Tumor

United States
Cullinan Therapeutics Inc.

Recruiting

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Mural Oncology, Inc

Recruiting

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3)

Advanced Solid Tumor

United States, Spain
1200 Pharma, LLC

Terminated

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Advanced Solid Tumor

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Pazopanib and ARQ 197 for Advanced Solid Tumors

Solid Tumor

United States
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

Unspecified Adult Solid Tumor, Protocol Specific

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Children With Advanced Solid Tumors

Unspecified Childhood Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Irinotecan in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

3-AP in Treating Patients With Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

SJG-136 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Unknown

Vinorelbine in Treating Patients With Metastatic or Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States

Clinical Trials on Tumor, Solid in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations